quigley - PRPH

PRPH

Close Chg Chg %
0.45 -0.01 -1.28%

Closed Market

0.45

-0.01 (1.28%)

Volume: 532.28K

Last Updated:

Dec 31, 2025, 4:00 PM EDT

Company Overview: quigley - PRPH

PRPH Key Data

Open

$0.45

Day Range

0.43 - 0.46

52 Week Range

0.41 - 9.35

Market Cap

$2.71M

Shares Outstanding

6.02M

Public Float

5.59M

Beta

-0.64

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$7.53

Yield

0.00%

Dividend

$0.30

EX-DIVIDEND DATE

May 24, 2022

SHORT INTEREST

N/A

AVERAGE VOLUME

2.53M

 

PRPH Performance

1 Week
 
-13.94%
 
1 Month
 
-78.58%
 
3 Months
 
-92.00%
 
1 Year
 
-94.09%
 
5 Years
 
-99.51%
 

PRPH Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About quigley - PRPH

ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. It operates through the Diagnostic Services and Consumer Products segment. The Diagnostic Services segment includes COVID-19 and other diagnostic testing services. The Consumer Products segment consists of the manufacturing, retail customers, and personal genomics products and services. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Garden City, NY.

PRPH At a Glance

ProPhase Labs, Inc.
711 Stewart Avenue
Garden City, New York 11530
Phone 1-215-345-0919 Revenue 6.77M
Industry Pharmaceuticals: Other Net Income -53,364,000.00
Sector Health Technology Employees 96
Fiscal Year-end 12 / 2025
View SEC Filings

PRPH Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.288
Price to Book Ratio 3.076
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.231
Enterprise Value to Sales 5.818
Total Debt to Enterprise Value 0.624

PRPH Efficiency

Revenue/Employee 70,520.833
Income Per Employee -555,875.00
Receivables Turnover 0.338
Total Asset Turnover 0.087

PRPH Liquidity

Current Ratio 0.953
Quick Ratio 0.918
Cash Ratio 0.021

PRPH Profitability

Gross Margin -2.216
Operating Margin -570.591
Pretax Margin -625.258
Net Margin -788.242
Return on Assets -63.851
Return on Equity -174.581
Return on Total Capital -155.124
Return on Invested Capital -106.131

PRPH Capital Structure

Total Debt to Total Equity 334.19
Total Debt to Total Capital 76.969
Total Debt to Total Assets 38.881
Long-Term Debt to Equity 244.866
Long-Term Debt to Total Capital 56.396
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Quigley - PRPH

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
79.04M 122.65M 44.38M 6.77M
Sales Growth
+444.59% +55.17% -63.81% -84.75%
Cost of Goods Sold (COGS) incl D&A
37.05M 51.99M 28.14M 6.92M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.93M 5.06M 6.70M 6.64M
Depreciation
3.56M 2.64M 3.52M 4.66M
Amortization of Intangibles
1.37M 2.42M 3.18M 1.99M
COGS Growth
+273.98% +40.32% -45.87% -75.41%
Gross Income
41.99M 70.65M 16.24M (150.00K)
Gross Income Growth
+811.59% +68.27% -77.02% -100.92%
Gross Profit Margin
+53.12% +57.61% +36.59% -2.22%
2021 2022 2023 2024 5-year trend
SG&A Expense
32.19M 47.06M 37.85M 38.48M
Research & Development
520.00K 652.00K 1.42M 594.00K
Other SG&A
31.67M 46.41M 36.43M 37.88M
SGA Growth
+274.66% +46.20% -19.56% +1.66%
Other Operating Expense
- - - -
-
Unusual Expense
- 3.99M 76.00K 333.00K
EBIT after Unusual Expense
5.81M 23.52M (21.61M) (38.96M)
Non Operating Income/Expense
642.00K 153.00K 88.00K (18.00K)
Non-Operating Interest Income
- 642.00K 153.00K 78.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.15M 764.00K 1.27M 3.35M
Interest Expense Growth
+289.15% -33.45% +66.88% +162.75%
Gross Interest Expense
1.15M 764.00K 1.27M 3.35M
Interest Capitalized
- - - -
-
Pretax Income
5.30M 22.91M (22.80M) (42.33M)
Pretax Income Growth
+328.07% +331.82% -199.53% -85.66%
Pretax Margin
+6.71% +18.68% -51.37% -625.26%
Income Tax
(968.00K) 4.45M (6.02M) 7.20M
Income Tax - Current - Domestic
1.32M 4.58M 1.06M 45.00K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(2.29M) (138.00K) (7.07M) 7.15M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
6.27M 18.46M (16.78M) (49.52M)
Minority Interest Expense
- - - -
-
Net Income
6.27M 18.46M (16.78M) (49.52M)
Net Income Growth
+369.69% +194.32% -190.90% -195.11%
Net Margin Growth
+7.94% +15.05% -37.81% -731.54%
Extraordinaries & Discontinued Operations
- - - (3.84M)
-
Discontinued Operations
- - - (3.84M)
-
Net Income After Extraordinaries
6.27M 18.46M (16.78M) (53.36M)
Preferred Dividends
- - - -
-
Net Income Available to Common
6.27M 18.46M (16.78M) (53.36M)
EPS (Basic)
4.1346 11.6523 -9.753 -26.0783
EPS (Basic) Growth
+306.11% +181.82% -183.70% -167.39%
Basic Shares Outstanding
1.52M 1.58M 1.72M 2.05M
EPS (Diluted)
3.9542 10.2386 -9.753 -26.0783
EPS (Diluted) Growth
+297.12% +158.93% -195.26% -167.39%
Diluted Shares Outstanding
1.84M 1.87M 1.72M 2.05M
EBITDA
14.74M 28.66M (14.91M) (31.98M)
EBITDA Growth
+517.81% +94.46% -152.05% -114.45%
EBITDA Margin
+18.64% +23.36% -33.60% -472.45%

Snapshot

Average Recommendation BUY Average Target Price 160.00
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate N/A
Last Quarter’s Earnings -1.60 Median PE on CY Estimate N/A
Year Ago Earnings -26.10 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A N/A N/A
Mean Estimate N/A N/A N/A N/A
High Estimates N/A N/A N/A N/A
Low Estimate N/A N/A N/A N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Quigley - PRPH

Date Name Shares Transaction Value
Sep 12, 2025 Ted William Karkus CEO & CHAIRMAN; Director 500,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Stuart Hollenshead Chief Operating Officer 500,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Quigley in the News